Immune Targeting Systems (ITS), a company developing synthetic vaccines for mutating viruses such as influenza, has secured follow-on funding.

Immune Targeting Systems (ITS), a London-based company developing synthetic vaccines for mutating viruses such as influenza, has secured follow-on funding.

The money is from an international syndicate of backers, which has now invested £4.5 million in ITS. The syndicate includes the government-backed London Technology Fund, Sweden-based HealthCap, Swiss investor Novartis Venture Fund and French firm Truffle Capital.

The funding will help ITS get its vaccine into clinics as well as strengthening its board and management team.

ITS’ vaccines, while initially aimed at seasonal and pandemic influenza, have potential applications in the treatment of Hepatitis C and AIDS.